Christopher Hall Sells 80,091 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 80,091 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $11.02, for a total transaction of $882,602.82. Following the completion of the sale, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $2,600,565.72. This trade represents a 25.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Up 3.8%

Shares of Personalis stock opened at $11.40 on Friday. The firm has a market cap of $1.19 billion, a PE ratio of -11.18 and a beta of 1.96. Personalis, Inc. has a 12-month low of $3.84 and a 12-month high of $11.85. The company’s fifty day simple moving average is $6.86 and its two-hundred day simple moving average is $8.10.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The company had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.49 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. As a group, sell-side analysts expect that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PSNL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Needham & Company LLC lifted their target price on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research note on Saturday. Morgan Stanley dropped their price objective on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, BTIG Research dropped their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Institutional Investors Weigh In On Personalis

Several hedge funds have recently bought and sold shares of PSNL. Royal Bank of Canada raised its holdings in Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after buying an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its stake in shares of Personalis by 75.6% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after buying an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after buying an additional 101,706 shares in the last quarter. Focus Partners Wealth bought a new position in shares of Personalis in the first quarter worth approximately $47,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Personalis by 505.6% in the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after buying an additional 24,621 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.